Steady Expansion Forecast for ACE Inhibitors Market, Projected to Reach $9.6 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

ACE Inhibitors Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for ACE inhibitors has seen consistent growth in the last few years. It is projected to increase from $7.15 billion in 2024 to $7.48 billion in 2025 with a compound annual growth rate (CAGR) of 4.6%. The upward trend in the past can be credited to a surge in cardiovascular disease cases, an aging population, effective clinical outcomes and safety, increasing diabetes prevalence, along with regulatory approvals and guidelines.

ACE Inhibitors Market Size Forecast: What's the Projected Valuation by 2029?
In the upcoming years, the ACE inhibitors market is anticipated to experience robust growth, expanding to a valuation of "$9.6 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 6.4%. Factors contributing to this predicted growth include the escalating global prevalence of cardiovascular diseases, broadening guidelines for hypertension treatment, advancements in combination therapies, emphasis on heart failure management, and increased awareness and accessibility to healare. Expected trends for this period are kidney protection focus, preference for renin-angiotensin system inhibitors, competition from generic brands and cost pressures, patient-oriented approaches in healare, along with regulatory changes and considerations for safety.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

What Are the Drivers Transforming the ACE Inhibitors Market?
Growing occurrences of hypertension-related disorders are projected to propel the expansion of the ACE inhibitors market in the future. Hypertension, clinically referred to as high blood pressure, is a disorder signified by increased pressure in the blood vessels. ACE inhibitors, also recognized as angiotensin-converting enzyme inhibitors, are a class of drugs employed for the management and treatment of high blood pressure. These drugs work by relaxing blood vessels, culminating in a lowered blood pressure and enhanced blood circulation. For instance, the World Health Organization, a specialized division of the United Nations based in Switzerland, released data in March 2023 stating that nearly 1.28 billion adults ranging in age from 30 to 79 globally suffer from hypertension, with the majority (two-thirds) hailing from low to middle-income countries. In the last 30 years, the count of people between 30-79 years suffering from hypertension has risen by 650 million. Worryingly, an estimated 46% of adults with hypertension don't even know they have it due to the lack of a proper diagnosis. Therefore, the mounting occurrence of hypertension-related disorders is triggering the growth of the ACE inhibitors market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

What Long-Term Trends Will Define the Future of the ACE Inhibitors Market?
The ACE inhibitors market is witnessing a significant growth due to an increasing trend towards product innovation. Major players in this market are channeling their resources towards developing cutting-edge products to bolster their market standing and secure a competitive edge. Travere Therapeutics, a renowned biopharmaceutical company based in the US, exemplified this trend when it received FDA approval for FILSPARI (sparsentan) - a novel non-immunosuppressive treatment for patients with IgA nephropathy (IgAN) in February 2023. The therapy, which includes systemic glucocorticoids, ACE inhibitors, and angiotensin-receptor blockers (ARBs), sets itself apart as the sole non-immunosuppressive drug approved. It's also a once-a-day oral medication intended for adults suffering from primary IgAN who are at risk of rapid disease progression and usually have a UPCR of less than 1.5 g/g and proteinuria.

Which Segments in the ACE Inhibitors Market Offer the Most Profit Potential?
The ACE inhibitors market covered in this report is segmented -

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents
2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs
3) By Dosage Form: Oral Tablets, Oral Solutions
4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications
5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:
1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril
2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril
3) By Phosphonate-Containing Agents: Fosinopril

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

Which Firms Dominate the ACE Inhibitors Market by Market Share and Revenue in 2025?
Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy's Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healare Limited, AbbVie Inc., Sandoz Group AG, Accord Healare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Which Regions Offer the Highest Growth Potential in the ACE Inhibitors Market?
North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10671

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.